June 16, 2014
Authored and Edited by B. Brett Heavner
On June 12, 2014, the Supreme Court issued its decision in Pom Wonderful LLC v. Coca-Cola Co., No. 12-761, holding that Lanham Act false-advertising claims are not pre-empted by the Federal Food, Drug, and Cosmetic Act (“FDCA”) or related Food and Drug Administration (“FDA”) regulations. In that case, POM Wonderful LLC (“POM”), a pomegranate-juice beverage producer, sued its competitor, Coca-Cola Company (“Coca-Cola”), under § 43(a) of the Lanham Act, claiming that Coca-Cola’s “Pomegranate Blueberry” juice beverage was falsely labeled because, in reality, the beverage contained about “99.4% apple and grape juices,” and only “0.3% pomegranate juice” and “0.2% blueberry juice.” Slip op. at 5-6. In proceedings below, Coca-Cola successfully argued that POM’s Lanham Act claim should be dismissed because it was pre-empted by the FDCA and FDA regulations, which permitted Coca-Cola’s type of beverage labeling. Specifically, the FDA allows beverage labels to list flavoring juices that are not the predominant juice contained in the beverage.
The Supreme Court reversed the dismissal. First, the Court determined that the FDCA only pre-empted certain state laws and did not pre-empt other federal statutes, such as the Lanham Act. Second, the Court found that, as a matter of statutory interpretation, the FDCA does not preclude private causes of action under the Lanham Act merely because FDA regulations touch on the same advertising alleged to be false or misleading in the Lanham Act claim. FDCA’s and the Lanham Act’s false-advertising provisions complement each other. Each has its own separate scope and purpose. The FDCA and FDA regulations focus on consumer safety, while the Lanham Act protects competitors from misleading or unfair marketing strategies. Unlike the purely administrative role of the FDCA, the Lanham Act motivates businesses to behave well by subjecting them to liability to competitors injured by unfair marketing.
Third, as a practical matter, precluding Lanham Act liability for false advertising would actually create a less effective enforcement scheme for food and beverage labeling. The FDA does not preapprove food and beverage labeling, and does not necessarily pursue enforcement measures against all problem labels. If Lanham Act claims were precluded, false labels that the FDA did not take action against would be immune from any consequences. Congress could not have intended the FDCA to result in less protection for the public from misleading labels.
The case was reminded for a determination of whether the Coca-Cola labels violated the Lanham Act.
false advertising, Food and Drug Administration (FDA), Section 43(a), Supreme Court of the United States (SCOTUS)
Copyright © 2014 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Webinar
Obviousness of Biologics Inventions: Strategies for Biologics Claims in the U.S., Europe, and China
May 28,2024
Webinar
Prosecution First Blog
May 3, 2024
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
INCONTESTABLE® Blog
Courts and Legislators Addressing the Right of Publicity in the Age of AI
April 30, 2024
Federal Circuit IP Blog
March 21, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.